Understanding the Neurohormonal Sensitivity Beyond the Premenstrual Phase
If your premenstrual phase feels less like a temporary inconvenience and more like a total shift in how you experience the world, then you are not alone and you are not imagining it.
Premenstrual Dysphoric Disorder (PMDD) is a severe, neurobiological condition that affects approximately 3-8% of menstruating individuals worldwide (1). Despite its prevalence, it remains widely misunderstood, frequently misdiagnosed and routinely dismissed as “just bad PMS” (2).
To advocate for your body, you first need clear, evidence-led language. Here is a baseline look at what PMDD actually is, what causes it and how it manifests.
Beyond Moodiness
PMDD is recognised as a distinct diagnosis within the depressive episodes chapter of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (3).
Unlike general premenstrual syndromes which can cause physical discomfort and mild emotional changes, PMDD causes significant psychological distress and functional impairment (2). It is characterised by severe mood shifts, debilitating anxiety, intense irritability and overwhelming fatigue that consistently appear during the luteal phase of the menstrual cycle (4). Luteal phase is the window between ovulation and the start of your period.
When menstruation begins (or within a few days after), these symptoms typically fade or resolve completely, offering a brief window of relief before the cycle resets (3).
Key takeaway: PMDD is not an emotional weakness or an inability to cope with stress. It is a predictable, cycle-bound medical condition with direct physiological roots.
A Neurohormonal Sensitivity
A common misconception is that people with PMDD have “abnormal” hormone levels.
In reality, clinical research shows that individuals with PMDD usually have completely normal levels of oestrogen and progesterone (5). The issue is not the quantity of circulating hormones, it is how the central nervous system responds to the standard hormonal fluctuations (1).
The steroid trigger: During the luteal phase, progesterone breaks down into a potent neurosteroid called allopregnanolone (ALLO) (1).
Receptor dysregulation: In a typical brain, ALLO interacts with GABA-A receptors in the central nervous system to produce anxiolytic (calming), stress-reducing effects (4).
The paradoxical response: In individuals with PMDD, altered GABA-A receptor subunit sensitivity causes a paradoxical reaction to normal hormonal shifts in ALLO, triggering severe anxiety, emotional dysregulation and distress (1, 4).
Essentially, PMDD is a severe cellular sensitivity to normal, healthy hormonal fluctuations.
Core Symptoms to Track
While physical symptoms such as bloating, breast tenderness and joint pain often accompany PMDD, the core diagnostic criteria requires the presence of prominent psychological and affective shifts (3).
Severe mood swings (sudden sadness, tearfulness or extreme sensitivity to rejection)
Marked irritability or anger, frequently leading to increased interpersonal conflicts
Depressed mood, feelings of hopelessness or severe self-critical thoughts
Anxiety, tension or feeling constantly on edge
Brain fog, difficulty concentrating or feeling overwhelmed/out of control
Profound fatigue or a sudden drop in physical energy
Navigating the Path Forward
Recognising PMDD is the first step towards reclaiming your agency. Because there is no single blood or laboratory test to diagnose PMDD, clinical guidelines require daily prospective symptom tracking over at least two consecutive menstrual cycles to confirm the timing pattern (2, 3).
If this resonates with your lived experience, know that your symptoms are real, your biological response is valid and evidence-based support is available.
Note for self-advocacy: If you suspect you are experiencing PMDD, start logging your symptoms daily alongside your cycle phase. Bringing multi-cycle tracking data to a trusted healthcare provider is the most effective way to begin a clinical conversation.
References & Clinical Reading
Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. Allopregnanolone and mood disorders. Progress in Neurobiology [Internet]. 2014 Feb;113:88–94. Available from: http://dx.doi.org/10.1016/j.pneurobio.2013.07.005
Yonkers KA, O’Brien PS, Eriksson E. Premenstrual syndrome. The Lancet [Internet]. 2008 Apr [cited 2026 Aug 20];371(9619):1200–10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118460/
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Diagnostic and Statistical Manual of Mental Disorders [Internet]. 5th edn 2013 May 22;5(5). Available from: https://doi.org/10.1176/appi.books.9780890425596
Hantsoo L, Epperson CN. Premenstrual dysphoric disorder: Epidemiology and treatment. Current Psychiatry Reports [Internet]. 2015;17(11). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890701/
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine [Internet]. 1998 Jan 22;338(4):209–16. Available from: https://www.nejm.org/doi/10.1056/NEJM199801223380401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov
